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Research Article
Breast Cancer Incidence After Risk-Reducing Salpingo-
Oophorectomy in BRCA1 and BRCA2 Mutation Carriers
Ingrid E. Fakkert1, Marian J.E. Mourits2, Liesbeth Jansen3, Dorina M. van der Kolk4, Kees Meijer3,
Jan C. Oosterwijk4, Bert van der Vegt5, Marcel J.W. Greuter6, and Geertruida H. de Bock1
Abstract
Premenopausal risk-reducing salpingo-oophorectomy (RRSO) in BRCA1/2 mutation carriers effectively
reduces ovarian cancer risk, but also reduces breast cancer risk. Breast cancer risk reductions up to 50%have
been reported for both BRCA1 and BRCA2mutation carriers, but recent prospective studies were not able to
reproduce this finding for BRCA1 mutation carriers.
Breast cancer incidence after RRSO was assessed in a consecutive series of 104 BRCA1 and 58 BRCA2
mutation carriers. On the basis of data from our own centre, and assuming a 50% risk reduction through
RRSO at premenopausal age, we expected to find 8 breast cancers (range 6–10) in this population for the
reported screening period (532 women-years).
In 162 carriers with a median age of 41 years at RRSO, 13 incident breast cancers were diagnosed. In
BRCA1mutation carriers, 12 incident breast cancers were found compared with 5 (range 3–6) expected and
in BRCA2 mutation carriers 1 breast cancer was found compared with 3 (range 2–5) expected.
Breast cancer incidence after premenopausal RRSO is still high, especially in BRCA1 mutation carriers.
Previously reported breast cancer risk reductions up to 50% were not confirmed. As a consequence,
continued intensive screening for breast cancer is warranted in BRCA1 and BRCA2 mutation carriers after
RRSO. Cancer Prev Res; 5(11); 1291–7. 2012 AACR.
Introduction
Women with a proven BRCA1 or BRCA2mutation have
a risk for developing breast cancer of 40% to 80% by the
age of 70 (1, 2). Ovarian cancer risk by the age of 70 is
40% for BRCA1 and 18% for BRCA2 mutation carriers (1,
2) A study by van der Kolk and colleagues (3) conducted
at our centre found cumulative risks of breast cancer of
71% [95% confidence interval (CI), 67%–82%) in BRCA1
and 88% (95% CI, 82%–93%) in BRCA2 mutation car-
riers by the age of 70. These risks were at the high end of
the spectrum compared with other studies, especially for
BRCA2 mutation carriers. The authors hypothesized that
this could be due to skewing towards testing in women
affected with cancer, competing risks of mortality from
ovarian cancer in BRCA1 mutation carriers, or missing of
BRCA2 mutation families with lower cancer penetrance
that fail to meet the age-related criteria for mutation
testing (3).
BRCA1 and BRCA2 mutation carriers are counseled on
different risk-reducing strategies, either screening or pro-
phylactic surgery. Breast cancer screening with clinical
breast examination (CBE), mammography, and MRI is
effective in detecting early-stage breast cancer in mutation
carriers (4–8). For ovarian cancer, current screening proto-
cols are ineffective in detecting early-stage ovarian cancer (9,
10). Risk-reducing salpingo-oophorectomy (RRSO) is effec-
tive in reducing the risk of ovarian cancer (HR, 0.21; 95%
CI, 0.12–0.39) (11). After counseling, RRSO is chosen by
almost all BRCA1 and BRCA2 mutation carriers at our
centre.
Besides reducing ovarian cancer risk, RRSO has been
shown to reduce breast cancer risk in mutation carriers. A
large meta-analysis found risk reductions of 50% associated
with RRSO in both BRCA1 and BRCA2 mutation carriers
(BRCA1: HR, 0.47; 95% CI, 0.35–0.64; BRCA2: HR, 0.47;
95% CI, 0.26–0.84; ref. 11). The effect of RRSO on breast
cancer risk was suggested to be stronger in women at premen-
opausal age, as greater risk reductions were found in women
who had surgery before the age of 40 to 50 years (12, 13).
However, it has been suggested that the effect of RRSO
differs between BRCA1 and BRCA2 mutation carriers (14,
15). In a study of Shah and colleagues (15), in 51 BRCA1
and 41 BRCA2 mutation carriers, 11 new breast cancers
were found, all within BRCA1 mutation carriers. The
percentage of women with RRSO was equal in women
who did and did not develop breast cancer (87% vs. 82%,
P ¼ 0.754; ref. 15).
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We aimed to study the incidence of breast cancer after
RRSO at premenopausal age in BRCA1 and BRCA2 muta-




All women with 1 or 2 breasts in situ, who were 51 years
old or younger (mean menopausal age in the Netherlands;
ref. 16) at the time of RRSO, were consecutively selected
from a prospective cohort of BRCA1/2 mutation carriers
who were enrolled in the surveillance program for hered-
itary breast and ovarian cancer at the University Medical
Center Groningen (UMCG; Groningen, The Netherlands)
from September 1995 until January 2011. Women with
previous breast cancer were included, when breast cancer
screening continuedon the remainingbreast tissue.Women
in whom ovarian cancer was found on the RRSO specimen
were not included. Before this study, we analyzed a previous
version of this database (data up until 30 September, 2009)
to determine the effectiveness of breast cancer screening
after RRSO (17).
RRSO protocol
RRSO is advised from the age of 35 to 40 years in BRCA1
mutation carriers and 40 to 45 years in BRCA2 mutation
carriers (18). However, patients are counseled individually,
and actual timing of RRSO depends on personal circum-
stances such as previous breast cancer, family history of
cancer, previous or planned pregnancies, andmental accep-
tance of this definitive procedure. The operative procedure
is conducted by laparoscopy (19).
Breast cancer screening
Breast cancer screening in BRCA1/2 mutation carriers
was done according to the Dutch guidelines, with annual
complete breast examination (CBE), and mammography
and MRI alternating by 6 months since 2008 (18). Before
2008, CBE was conducted biannually and MRI was con-
ducted in women participating in the MRISC trial (MRI
screening for breast cancer in women with familiar or
genetic predisposition, ref. 20).
Data collection
All BRCA1/2 mutation carriers who visit our Family
Cancer Clinic are consecutively included in a prospective
cohort. If these women met our inclusion criteria, we
retrospectively retrieved relevant data from the patient files
in the hospital. Physician’s letters, pathology reports, and
imaging reports were used for data collection.
Informationon the typeofmutation, date of birth, date of
RRSO, and ever-use of hormonal replacement therapy after
RRSO was collected. For previous breast cancers, age of
diagnosis and conducted surgical procedure (breast-con-
serving therapy or mastectomy) were recorded. For breast
cancers diagnosed after RRSO, age at diagnosis and path-
ologic features were recorded: tumor type according to the
WHO classification, tumor size inmillimeters, tumor grade
(Elston–Ellis modification of Bloom–Richardson grading
system), receptor status [estrogen receptor (ER), progester-
one receptor (PR), and HER2 receptor], presence of ductal
carcinoma in situ (DCIS), and presence of lymph node
metastases. Patient datawere entered into an SPSS database.
Protection of the patient’s identity was guaranteed by a
patient-specific number. Those numbers were only retrace-
able to individual women when entered in the password-
protected hospital database, which is only accessible for
hospital employees who have a personal account. Comply-
ing with Dutch law, no further Institutional Review Board
approval was needed.
Statistical analysis
To present the study population and characteristics of
breast cancers discovered after RRSO, contingency tables
were used. Breast cancers detected after RRSO could
be prevalent, possibly prevalent or incident. Prevalent
breast cancerswere defined as breast cancers detectedwithin
6 months after RRSO. Possibly prevalent breast cancers
were defined as breast cancers detectedmore than 6months
after RRSO that we considered prevalent because the time
after RRSO was shorter than the estimated growing time of
the breast cancer. For all the invasive breast cancers diag-
nosed more than 6 months after RRSO, we estimated the
duration of time a breast cancer had been growing and
compared this with the time interval between RRSO and
detection of breast cancer. To estimate this time,we used the
formula for estimating tumor-doubling time in mutation
carriers based on age at tumor diagnosis as presented by
Tilanus-Linthorst and colleagues (21): log2 [doubling time
(years)] ¼ 7.75 þ 0.12 age. On the basis of the tumor-
doubling time, we estimated the time a tumor was growing
from the theoretical size at baseline of 5 mm (which is the
assumed detection threshold for invasive breast cancer on
MRI; refs. 22, 23) to the size at detection. If this estimated
time period was longer than the time period between RRSO
and tumor detection, we considered a breast cancer possibly
prevalent. Incident breast cancers were defined as breast
cancers detected more than 6 months after RRSO and not
possibly prevalent.
Duration of follow-up was calculated for each woman
from RRSO to diagnosis of incident breast cancer, to pro-
phylactic mastectomy, to one year after the last screening
visit, or to January 1, 2011. The analyses were conducted
using the SPAW software package, version 18.0 for Win-
dows (SPSS).
Breast cancers expected
To estimate the number of women who develop incident
breast cancer after RRSO based on womens’ ages at RRSO
and their ages during follow-up, we used the penetrance
curves for breast cancer in mutation carriers in our centre
as published by Van der Kolk and colleagues (3) and a 50%
risk reduction for breast cancer expected after RRSO
[BRCA1/2: HR, 0.49; (95% CI, 0.37–0.65); BRCA1: HR,
0.47; (95% CI, 0.35–0.64) and BRCA2: HR, 0.47 (95% CI
0.26–0.84); ref. 11].
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Results
Population characteristics
We analyzed the data of 162 women, 104 BRCA1 muta-
tion carriers and 58 BRCA2 mutation carriers (Table 1). At
the time of RRSO, median age was 41 years (range 30–51)
for BRCA1mutation carriers and 42 years (range 33–51) for
BRCA2mutation carriers (P¼ 0.013). At the time of RRSO,
25%of the BRCA1mutation carriers and 12%of the BRCA2
mutation carriers had a history of breast cancer (P¼ 0.066).
After RRSO, hormonal replacement therapy was prescribed
to 47% (68/146) of the women, all without previous breast
cancer. Total follow-up in this studywas 6,389months (532
women-years); 4,309 months (359 women-years), and
2,080 months (173 women-years) for BRCA1 and BRCA2
mutation carriers, respectively.
Breast cancers after RRSO
During thepost-RRSO screeningperiod, 18breast cancers
in 18 women were detected (34/1,000 women-years). Of
these, 16 were found in BRCA1mutation carriers (45/1,000
women-years) and 2 in BRCA2mutation carriers (12/1,000
women-years).
Of the 18 breast cancers diagnosed after RRSO, 3 were
found within 6 months after RRSO and were considered
prevalent breast cancers. On the basis of tumor-doubling
time calculations, we considered 2 breast cancers to be
possibly prevalent (Table 2). Leaving out 3 prevalent breast
cancers and 2 possibly prevalent breast cancers, there were
at least 13 incident breast cancers (24/1,000 women-years)
during the study period, 12 inBRCA1mutation carriers (33/
1,000 women-years) and 1 in a BRCA2mutation carrier (6/
1,000 women-years). Table 3 illustrates the number of
women expected to develop breast cancer compared with
the number observed. Table 4 illustrates the characteristics
of women who did and did not develop incident breast
cancer after RRSO.
Tumor characteristics
Of the 13 incident breast cancers detected after RRSO, 11
(86%) were invasive and 2 (15%)were DCIS (Table 5). In 4
of 11 (36%) invasive cancers, axillary lymph nodes were
positive. Histologic grade was higher in breast cancers from
BRCA1 mutation carriers than from BRCA2 mutation car-
riers (70%grade 3 vs. none, respectively). Of the 11 invasive
breast cancers, 9 (82%) were ER, PR, and HER2 negative
(triple negative), all in BRCA1 mutation carriers.
Discussion
In a consecutive group of 104 BRCA1 and 58 BRCA2
mutation carriers with RRSO at premenopausal age, breast
cancer screening at our Family Cancer Clinic revealed 18
breast cancers in 18 women during 532 women-years (34/
1,000 women-years), of which, 13 were incident breast
cancers (24/1,000 women-years). On the basis of breast
Table 1. Characteristics of the women at baseline (N ¼ 162)
BRCA1 (N ¼ 104) BRCA2 (N ¼ 58) Total (N ¼ 162) Statistics
Age at RRSO in years
Median (range) 40 (30–51) 42 (33–51) 41.0 (30–51) P ¼ 0.013a
40 years 50% (52/104) 28% (16/58) 42% (68/162) P ¼ 0.006a
Follow-up in months
Total 4,309 2,080 6,389
Median (range) 31 (3–228) 28 (2–159) 28 (2–228) P ¼ 0.681
Previous breast cancer
No 75% (78/104) 88% (51/58) 80% (129/162) P ¼ 0.066
Yes unilateral 20% (21/104) 12% (7/58) 17% (28/162)
Yes bilateral 5% (5/104) - 3% (5/162)
Age at onset of ﬁrst breast
cancer in years (N ¼ 33)
Median (range) 38 (29–49) 42 (32-50) 41.0 (29–50) P ¼ 0.330
Breast cancer therapy
BCT unilateral 39% (10/26) 71% (5/7) 46% (15/33) P ¼ 0.403
Mast unilateral 42% (11/26) 29% (2/7) 39% (13/33)
BCT bilateral 15% (4/26) — 12% (4/33)
BCT and Mast 4% (1/26) — 3% (1/33)
Hormonal replacement therapy use
No 53% (49/92) 54% (29/54) 53% (78/146) P ¼ 0.959
Yes 47% (43/92) 46% (25/54) 47% (68/146)
aP < 0.05 is signiﬁcant. Mann–Whitney U test for continuous variables, Fisher exact test for proportions.
Abbreviations: BCT: Breast-conserving therapy; Mast, mastectomy; if noted as BCT andMast, 1 breast is treated with BCT and 1 with
Mast; after RRSO.
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cancer incidence curves and a 50% risk reduction associated
with RRSO, we expected to find 8 (range 6–10) incident
breast cancers (15/1,000 women-years; refs. 3, 11). Several
factors may have contributed to this difference in expected
and observed breast cancer incidence after RRSO.
An important finding is that 12 incident breast cancers
developed in BRCA1 mutation carriers compared with 5
(range 3–6) expected. For BRCA2 mutation carriers, 1
incident breast cancer developed compared with 3 (range
2–5) breast cancers expected. The risk reduction associated
with RRSO might be smaller in BRCA1 than in BRCA2
mutation carriers. The same hypothesis was suggested by
Shah and colleagues (15); they found 9 new tumors after
RRSO in45BRCA1mutation carriers andnone in35BRCA2
mutation carriers. Kauff and colleagues (24) also showed a
significant breast cancer risk reduction for BRCA2mutation




















1 BRCA1 37 LC 7 1.2 54.8 1.8
2 BRCA1 38 DCIS n.d. n.d. 14.8 n.d.
3 BRCA1 45 IDC 25 2.4 27.4 19.1
4 BRCA1 45 IDC 14 2.4 12.6 10.6
5 BRCA1 43 IDC 3 2.0 7.2 -4.4
6 BRCA2 52 IDC 11 4.2 19.8 14.4
7 BRCA1 36 IDC 8 1.1 10.3 2.3
8 BRCA1 41 DCIS 13 1.7 12.4 n.d.
9 BRCA1 47 IDC 30 2.8 20.9 21.6b
10 BRCA1 55 IDC 16 5.4 228.4 27.2
11 BRCA1 42 IDC 9 1.8 42.5 4.7
12 BRCA1 53 IDC 11 4.6 48.3 15.7
13 BRCA1 52 GRCCC 11 4.2 95.5 14.4
14 BRCA1 41 IDC 20 1.7 6.7 10.2b
15 BRCA1 47 IDC 11 2.8 78.3 9.5
aExcluded were prevalent cancers found within 6 months of RRSO
bPossibly prevalent tumors based on tumor doubling time calculations.
Abbreviations: GRCCC, glycogen rich clear cell carcinoma; IDC, invasive ductal carcinoma; LC, lobular carcinoma; n.d, no data, tumor
doubling time was not calculated for DCIS.






(N ¼ 162, total follow-up 532 years)
Number of women with incident breast cancer 16 8 (range 6–10) 13
In 1,000 women years 30 15 24
BRCA1 mutation
(N ¼ 104, total follow-up 359 years)
Number of women with incident breast cancer 10 5 (range 3–6) 12
In 1,000 women years 28 14 33
BRCA2 mutation
(N ¼ 58, total follow-up 173 years)
Number of women with incident breast cancer 6 3 (range 2–5) 1
In 1,000 women years 35 17 6
aEstimates based on the Van der Kolk penetrance curves (3).
bRisk reduction: 50% [BRCA1/2: HR, 0.49 (95% CI 0.37–0.65), BRCA1: HR, 0.47 (95% CI 0.35–0.63), and BRCA2: HR, 0.47 (95% CI
0.26–0.84; ref. 11].
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carriers but not for BRCA1 mutation carriers [BRCA1: HR,
0.61 (95% CI, 0.30–122), BRCA2: HR 0.28 (95% CI, 0.08–
0.92)] in a large prospective study with 190 BRCA1 and 113
BRCA2mutation carriers at risk for breast cancer after RRSO.
One explanation for this difference is that the effect of
RRSO might be less marked in BRCA1 mutation carriers,
because their breast cancers are often ER and PR negative
(14, 24). Of the invasive breast cancers found in BRCA1
mutation carriers in this study, 90% were ER and PR
negative.Nevertheless, a protective effect of RRSO inBRCA1
mutation carriers has been shown in several studies
(12, 13).
Others suggested that RRSO might inhibit breast cancer
growth in BRCA1 mutation carriers at tumorigenesis:
growth of ER and PR negative cells might be indirectly
induced by paracrine signals from ER- and PR-positive cells
that are influenced by estrogen and progesterone (15, 25).
Thus, breast cancer risk reduction after RRSO may take
longer to establish than the duration of follow-up in this
study,whichmaybe a second explanationwhywe sawmore
breast cancers than expected.
Another explanation for findingmore breast cancers than
expected may be the intensification of the breast cancer
screening regime since 2008, when MRI screening for all
BRCA1/2 mutation carriers was introduced at our centre.
Van der Kolks study contains information on breast cancer
incidence up to March 2008. Before 2008, MRI screening
was used in a small selection of women participating in the
MRISC study. It is known that after introducing a new
effective screening regimen, more breast tumors are found.
Warner and colleagues found a higher incidence of breast
cancer in the first 3 years after the introduction of MRI
screening in BRCA1/2 mutation carriers and an overall
higher incidence of DCIS (26). This effect has also been
shown in the general population after introduction of the
population-based breast cancer screening with mammo-
graphy (27, 28). This explanation is weakened by the fact
that this effect was not seen in BRCA2 mutation carriers.
Table 4. Characteristics of women who did and













BRCA1 92% (12/13) 62% (92/149)
BRCA2 8% (1/13) 38% (57/149)
Age at RRSO in years
40 years 54% (7/13) 41% (61/149)
>40 years 46% (6/13) 59% (88/149)
Follow-up after
RRSO in months
Median (range) 28 (2–218) 27 (7–228)
Previous breast cancer
No 69% (9/13) 77% (115/149)
Yesa 31% (4/13) 23% (34/149)
bEver-use of hormonal
replacement therapy
No 62% (8/13) 51% (73/142)
Yes 38% (5/13) 49% (69/142)
aPrevalent and possibly prevalent cancers were considered
previous breast cancer.
bHT: Hormonal replacement therapy after RRSO.
Table 5. Characteristics of incident breast











10 mm 4/12 (33)
10–20 mm 7/12 (58)
>20 mm 1/12 (8)
Histologic gradec
Grade 1 1/11 (9)
Grade 2 3/11 (27)













Grade 2 1/6 (17)




aExcluded were prevalent and possibly prevalent cancers
bTumor size could not be measured in one DCIS case.
cNot determined for DCIS.
Abbreviations: GRCCC, glycogen rich clear cell carcinoma;
IDC, invasive ductal carcinoma; LC, lobular carcinoma;
WHO, World health organization.
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A fourth explanation might be that RRSO is chosen by
women with especially high breast cancer risks. Although
eventually RRSO is chosen by almost allmutation carriers at
our centre, timing might be affected by family history and
previous breast cancers. As can be seen in Table 4, of the
womenwho developed breast cancer after RRSO, 54%were
younger than 40 years and 31% had previous breast cancer,
compared with 41% and 23% in the women who did not
develop breast cancer.
A last explanation might be the use of hormonal replace-
ment therapy after RRSO. In our study population, 47% of
thewomenused hormonal replacement therapy after RRSO
and this percentage was not higher in women with incident
breast cancer. Although it has been shown that short-term
use of hormonal replacement therapy does not negate the
effect of RRSO (29) and one study found an inversed
relation in hormonal replacement therapy use and breast
cancer incidence inBRCA1mutation carriers (30), hormon-
al replacement therapy does increase the risk of new and
recurrent breast cancer in women with previous breast
cancer (31, 32). On the contrary, a higher mortality was
seen in women with bilateral oophorectomy before the age
of 45 who did not use hormonal replacement therapy,
compared with those women who did (33). Theoretically,
it is plausible that hormonal replacement therapy use after
RRSOpartially negates the risk-reducing effect of RRSO, but
bias might be introduced if hormonal replacement therapy
ismore often prescribed towomenwith less breast cancer in
their family, or if survival is shorter in women who do not
use hormonal replacement therapy.Our study sample is too
small and follow-up to short to draw conclusions on this
issue. The effects of hormonal replacement therapy after
RRSO on the long-term breast cancer risk and survival
should be monitored carefully.
We aimed to study the incidence of breast cancer after
RRSO at premenopausal age. The strength of this study is
that we used an algorithm that incorporates an estimate of
growing time to exclude the effect of prevalent breast cancer
on the incidence of new breast cancers after RRSO. Small
sample size and short follow-up limit the possibilities to
identify risk factors for breast cancer after RRSO. Because
menopausal status at RRSO was not known for all women,
we chose to include all women with the age at RRSO of 51
years or younger, which can be a limitation. Although this is
the mean age of menopause in the Netherlands, some of
these women might have been postmenopausal at time of
RRSO, either due to natural or chemotherapy-induced
menopause. Furthermore, we estimated the amount of
breast cancer after RRSO with breast cancer penetrance
curves from our own centre. An ideal design would be a
randomized controlled trial with a RRSO and a surveillance
group. As surveillance is not effective andRRSO is chosen by
almost all mutation carriers at our centre, this design would
be unethical.
To conclude, the breast cancer incidence after premeno-
pausal RRSO is still high, especially in BRCA1 mutation
carriers.We couldnot confirm the expected risk reduction as
described by other authors. As a consequence, after RRSO,
continued surveillance with mammography and MRI for
breast cancer in BRCA1 and BRCA2 mutation carriers is
warranted.
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